Skip to main content

NEOliquid Biopsy Test

NEO New Oncology has launched NEOliquid, a non-invasive cancer diagnostics test that requires a little as 18 milliliters of blood. It identifies clinically relevant, cancer-specific point mutations, insertions, deletions, and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1 percent. NEOliquid comprises 39 genes relevant for the treatment of solid tumors. It enables parallel analysis of both the primary tumor as well as its metastases, capturing the entire heterogeneity of the disease, and can be applied to reveal additional possible therapeutic options for the patient, the company said in a statement. The product is applicable to patients with solid tumors, such as lung, skin, breast, stomach, intestinal or ovarian cancer, or in childhood malignancies such as neuroblastoma.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.